Immune Oncology Research Institute

Call Directions Website Contact the practice

Immune Oncology Research Institute A non-profit research foundation established in 2022 in Armenia, aimed to advance cancer research.

Armenia has officially become the first country in the world to grant marketing authorizations for Agenus’ innovative im...
09/10/2026

Armenia has officially become the first country in the world to grant marketing authorizations for Agenus’ innovative immunotherapy combination botensilimab and balstilimab (BOT+BAL). Issued by the Ministry of Health, this milestone decision marks the first global approval for either medicine, establishing an important precedent for advanced cancer care.

The conditional approvals cover their combined use in adult patients with microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received standard available therapies. Marketed in Armenia under the brand names Botvymo (botensilimab) and Evamplix (balstilimab), this regimen offers a much-needed treatment path for local patients as well as those traveling to Armenia for specialized oncological care.

Backed by robust clinical data from Phase 1b and Phase 2 studies published in leading peer-reviewed journals like Nature Medicine and Clinical Cancer Research, this regulatory clearance transitions the therapy from clinical development into authorized use. Beyond Armenia, Agenus will evaluate potential applications across Eurasian Economic Union member countries, reinforcing the combination's global impact in oncology.

🎉The Immune Oncology Research Institute (IMMONC) extends its sincere congratulations to Dr.Samvel Bardakhchyan, MD, PhD,...
04/10/2026

🎉The Immune Oncology Research Institute (IMMONC) extends its sincere congratulations to Dr.Samvel Bardakhchyan, MD, PhD, Co-Founder and Scientific Director of IMMONC, on the occasion of his birthday.

Dr. Bardakhchyan’s scientific leadership, professional expertise, and commitment to advancing oncology have been instrumental in shaping IMMONC’s research and clinical mission.

His dedication to scientific excellence, innovation, and the advancement of cancer care continues to inspire colleagues and contribute meaningfully to the oncology community.

On behalf of the entire IMMONC team, we wish Dr. Bardakhchyan good health, continued professional success, further scientific achievements, and many meaningful accomplishments in the years ahead.

𝐖𝐡𝐢𝐥𝐞 𝐜𝐫𝐢𝐬𝐞𝐬 𝐩𝐮𝐭 𝐥𝐢𝐯𝐞𝐬 𝐚𝐭 𝐫𝐢𝐬𝐤, 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐦𝐮𝐬𝐭 𝐤𝐞𝐞𝐩 𝐟𝐢𝐧𝐝𝐢𝐧𝐠 𝐚 𝐰𝐚𝐲 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐧𝐞𝐞𝐝 𝐢𝐭 𝐦𝐨𝐬𝐭.For years, Dr. Gevorg T...
26/09/2026

𝐖𝐡𝐢𝐥𝐞 𝐜𝐫𝐢𝐬𝐞𝐬 𝐩𝐮𝐭 𝐥𝐢𝐯𝐞𝐬 𝐚𝐭 𝐫𝐢𝐬𝐤, 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐦𝐮𝐬𝐭 𝐤𝐞𝐞𝐩 𝐟𝐢𝐧𝐝𝐢𝐧𝐠 𝐚 𝐰𝐚𝐲 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐧𝐞𝐞𝐝 𝐢𝐭 𝐦𝐨𝐬𝐭.

For years, Dr. Gevorg Tamamyan, CEO of the Immune Oncology Research Institute, has worked where medicine meets some of its hardest realities — childhood cancer, limited resources, unequal access to treatment, and communities where geography itself can become a barrier to survival.

Today, that journey reaches a new global stage.

𝐃𝐫. 𝐆𝐞𝐯𝐨𝐫𝐠 𝐓𝐚𝐦𝐚𝐦𝐲𝐚𝐧 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐧𝐨𝐦𝐢𝐧𝐚𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐑𝐞𝐩𝐮𝐛𝐥𝐢𝐜 𝐨𝐟 𝐁𝐨𝐭𝐬𝐰𝐚𝐧𝐚 𝐚𝐬 𝐚 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞 𝐟𝐨𝐫 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫-𝐆𝐞𝐧𝐞𝐫𝐚𝐥 𝐨𝐟 𝐭𝐡𝐞 World Health Organization (WHO).

Behind that nomination stands a philosophy shaped by years of seeing what unequal access to healthcare can mean for a human life.

In his own words:

“I have seen children survive when few believed they would. And I have seen children die simply because of where they were born.”

𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐲 𝐦𝐮𝐬𝐭 𝐧𝐨𝐭 𝐝𝐞𝐜𝐢𝐝𝐞 𝐰𝐡𝐨 𝐥𝐢𝐯𝐞𝐬.

These are not just words. They reflect a career built around one of medicine’s most difficult questions: how do we make sure care still reaches people when resources are limited, systems are under pressure, or circumstances stand between a patient and treatment?

Dr. Tamamyan describes his vision in these words:

“My vision is clear: a World Health Organization that delivers—faster, more effectively, and in true partnership with Member States—so that progress in health reaches every person, everywhere.”

For the Immune Oncology Research Institute, this nomination marks an important moment in a journey that began with patients and now reaches the global health stage.

𝐖𝐡𝐢𝐥𝐞 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝 𝐜𝐫𝐞𝐚𝐭𝐞𝐬 𝐝𝐢𝐬𝐭𝐚𝐧𝐜𝐞, 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐦𝐮𝐬𝐭 𝐤𝐞𝐞𝐩 𝐟𝐢𝐧𝐝𝐢𝐧𝐠 𝐚 𝐰𝐚𝐲 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐩𝐞𝐨𝐩𝐥𝐞.

🎉 We are pleased to wish a very Happy Birthday to our colleague, Elen Baloyan, MD, Clinical Research Physician at the Im...
22/09/2026

🎉 We are pleased to wish a very Happy Birthday to our colleague, Elen Baloyan, MD, Clinical Research Physician at the Immune Oncology Research Institute.

🔬 Elen is actively involved in clinical and global oncology research, with particular interests in lung cancer, immuno-oncology, molecular oncology, and improving access to cancer care in resource-limited settings.

🌍 Her dedication to research, education, and international collaboration represents the next generation of oncology professionals committed to advancing cancer care in Armenia and globally.

✨ We wish Elen continued success, impactful research, inspiration, and many new professional achievements in the year ahead.

🌍 We are proud to celebrate an important milestone for our team!Our Innovation and Development Director, Dr. Shushan Hov...
15/09/2026

🌍 We are proud to celebrate an important milestone for our team!

Our Innovation and Development Director, Dr. Shushan Hovsepyan, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. 🎗️

🧬 Her work in pediatric oncology, research, education, international collaboration, and global cancer communication continues to contribute to stronger partnerships and more innovative approaches in oncology.

👏 We congratulate Shushan on this important achievement and wish her every success in the upcoming UICC Board elections.

🔗 Read more on OncoDaily:
https://oncodaily.com/career/shushan-hovsepyan-585658

🏆 We are proud to share that IMMONC CEO and Co-Founder, Prof. Gevorg Tamamyan, has received the 2026 Global Health Catal...
11/09/2026

🏆 We are proud to share that IMMONC CEO and Co-Founder, Prof. Gevorg Tamamyan, has received the 2026 Global Health Catalyst Distinguished Leader Award.

This is an important recognition of his work and contribution to oncology and global health, and a proud moment for the entire IMMONC team.

For us, it is especially meaningful to see the leadership behind IMMONC recognized internationally. It gives us even more motivation to continue developing clinical research, strengthening international collaboration, and contributing to better cancer care in Armenia and beyond. 🌍

Congratulations to Prof. Tamamyan on this well-deserved recognition! 👏

We are proud to congratulate Dr. Amalya Sargsyan, Lead of the Adult Solid Tumors Team and IO Accessibility Research Lead...
03/09/2026

We are proud to congratulate Dr. Amalya Sargsyan, Lead of the Adult Solid Tumors Team and IO Accessibility Research Lead at the Immune Oncology Research Institute, on receiving the ESMO - European Society for Medical Oncology Leadership & Career Development Award. 🏆

As part of this important next step in her professional journey, Amalya will join Prof. Sandra Strauss at UCL Health in London to further develop her expertise in Sarcoma and Adolescent & Young Adult (AYA) oncology, with a particular focus on osteosarcoma. 🇬🇧🔬🩺

Amalya has consistently combined clinical work, research, advocacy for better access to cancer care, and international collaboration with one central goal: improving outcomes for patients and strengthening oncology care in Armenia.
Her growing focus on sarcoma and AYA oncology represents an important area for the future of cancer care in our country, and we are proud to see her continue this journey alongside internationally recognized experts in the field.🌍✨

Congratulations, Amalya, on this well-deserved achievement. 🎉 We look forward to seeing the knowledge, collaborations, and experience from this opportunity translated into meaningful progress for patients in Armenia and globally. 🤝🌟

We congratulate our colleague, Gohar Geghamyan, on her birthday! 🎉The IMMONC team wishes Gohar continued professional gr...
24/08/2026

We congratulate our colleague, Gohar Geghamyan, on her birthday! 🎉

The IMMONC team wishes Gohar continued professional growth, inspiring opportunities, meaningful achievements, and success in every new endeavor.

May the year ahead be filled with new ideas, rewarding experiences, and many memorable moments.

🧬 What if we could know who is most likely to benefit from immunotherapy — before treatment even begins?In a new Nature ...
10/08/2026

🧬 What if we could know who is most likely to benefit from immunotherapy — before treatment even begins?

In a new Nature Medicine study, Wanxiang Shen and colleagues introduce COMPASS, a pan-cancer AI foundation model designed to predict response to immune checkpoint inhibitors using pretreatment tumor transcriptomes. Trained on 10,184 tumors across 33 cancer types and validated across 16 independent clinical cohorts, COMPASS outperformed 22 existing prediction methods. But what makes this work particularly compelling is that the model does more than predict outcomes — it also helps explain the biology behind them, connecting response and resistance to mechanisms such as IFN-γ signaling, cytotoxic T-cell activity, TGF-β signaling and immune exclusion. 🔬🤖

This points toward a potentially important shift in precision immuno-oncology: moving beyond isolated biomarkers toward AI systems that can interpret the complex interaction between tumors and the immune system. From better patient selection to understanding resistance and identifying new therapeutic strategies, the implications are substantial. If you work in immuno-oncology, precision medicine or AI-driven cancer research, this is a study worth reading in full. 🎯

Read the full article here: https://www.nature.com/articles/s41591-026-04502-7

We are proud to share that Dr. Ruzanna Papyan, Lead of IMMONC’s Pediatric Hematology and Oncology Team, has co-authored ...
31/07/2026

We are proud to share that Dr. Ruzanna Papyan, Lead of IMMONC’s Pediatric Hematology and Oncology Team, has co-authored a newly published article in Pediatric Blood & Cancer📚🔬

This publication is more than an academic milestone—it reflects the importance of locally generated evidence, international collaboration, and persistent research in improving care for children, adolescents, and young adults with cancer.

Congratulations to Dr. Papyan and all contributing authors on this important achievement! 🎉🌍

Read the full article here:
https://onlinelibrary.wiley.com/doi/10.1002/1545-5017.70556

Address

7 Nersisyan
Yerevan
0014

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Telephone

+37441310048

Website

Alerts

Be the first to know and let us send you an email when Immune Oncology Research Institute posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Immune Oncology Research Institute:

Shortcuts

Share

Category